KR101481643B1 - 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물 - Google Patents

로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물 Download PDF

Info

Publication number
KR101481643B1
KR101481643B1 KR20137013119A KR20137013119A KR101481643B1 KR 101481643 B1 KR101481643 B1 KR 101481643B1 KR 20137013119 A KR20137013119 A KR 20137013119A KR 20137013119 A KR20137013119 A KR 20137013119A KR 101481643 B1 KR101481643 B1 KR 101481643B1
Authority
KR
South Korea
Prior art keywords
plga
acid
rotigotine
weight
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR20137013119A
Other languages
English (en)
Korean (ko)
Other versions
KR20130130727A (ko
Inventor
아이핑 왕
유신 리
완후이 류
카오시앙 순
준 리
리팡 순
Original Assignee
산동 루예 파마슈티칼 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산동 루예 파마슈티칼 컴파니 리미티드 filed Critical 산동 루예 파마슈티칼 컴파니 리미티드
Publication of KR20130130727A publication Critical patent/KR20130130727A/ko
Application granted granted Critical
Publication of KR101481643B1 publication Critical patent/KR101481643B1/ko
Assigned to 제네오라 파마 (스자좡) 컴퍼니 리미티드 reassignment 제네오라 파마 (스자좡) 컴퍼니 리미티드 권리의 전부이전등록 Assignors: 산동 루예 파마슈티칼 컴파니 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR20137013119A 2010-11-25 2011-11-25 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물 Active KR101481643B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010576447 2010-11-25
CN201010576447.5 2010-11-25
PCT/CN2011/001958 WO2012068783A1 (en) 2010-11-25 2011-11-25 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative

Publications (2)

Publication Number Publication Date
KR20130130727A KR20130130727A (ko) 2013-12-02
KR101481643B1 true KR101481643B1 (ko) 2015-01-12

Family

ID=46145374

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20137013119A Active KR101481643B1 (ko) 2010-11-25 2011-11-25 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물

Country Status (14)

Country Link
US (1) US9265835B2 (https=)
EP (1) EP2642993B1 (https=)
JP (2) JP6006225B2 (https=)
KR (1) KR101481643B1 (https=)
CN (1) CN103458895B (https=)
AU (1) AU2011334494B2 (https=)
BR (1) BR112013012726B1 (https=)
CA (1) CA2816288C (https=)
ES (1) ES2572948T3 (https=)
MY (1) MY165003A (https=)
PH (1) PH12013500923A1 (https=)
PL (1) PL2642993T3 (https=)
RU (1) RU2589700C2 (https=)
WO (1) WO2012068783A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8682462B2 (en) 2011-08-13 2014-03-25 Colin M. Leonard Systems and methods for dynamic audio processing
US11074031B1 (en) 2016-09-06 2021-07-27 Colin Leonard Systems and methods for dynamic audio processing
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
CA2935311C (en) 2013-12-31 2018-11-27 Pb&B Sa Controlled release fatty acid compositions for use in body reconstruction and body-shaping
CN105310974B (zh) * 2014-08-01 2019-08-23 山东绿叶制药有限公司 罗替戈汀及其衍生物或其药用盐的植入剂
CN106474070B (zh) * 2015-08-26 2020-03-17 四川科伦药物研究院有限公司 一种克服停滞期、恒速释放疏水性药物的微球及制备方法
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
ES2855976T3 (es) * 2016-07-21 2021-09-27 Shandong luye pharmaceutical co ltd Behenato de rotigotina y procedimiento de fabricación y aplicación del mismo
WO2018045000A1 (en) 2016-08-30 2018-03-08 Dow Agrosciences Llc Picolinamides as fungicides
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
EP4104820A4 (en) * 2020-02-14 2024-04-17 G2GBIO, Inc. Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
WO2025243901A1 (ja) * 2024-05-21 2025-11-27 株式会社 SENTAN Pharma 注射製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012549A2 (en) * 1997-09-09 1999-03-18 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Controlled release microsphere delivery system
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
JP4927729B2 (ja) 2004-07-16 2012-05-09 オークウッド ラボラトリーズ，エル．エル．シー． 性腺刺激ホルモン放出ホルモンアンタゴニスト
CN1762495B (zh) 2004-09-21 2011-04-06 山东绿叶制药有限公司 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
JP5222550B2 (ja) 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012549A2 (en) * 1997-09-09 1999-03-18 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Controlled release microsphere delivery system
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법

Also Published As

Publication number Publication date
AU2011334494B2 (en) 2015-11-05
CN103458895B (zh) 2014-07-09
PH12013500923A1 (en) 2016-02-08
WO2012068783A1 (en) 2012-05-31
JP6067803B2 (ja) 2017-01-25
EP2642993A4 (en) 2014-05-14
RU2589700C2 (ru) 2016-07-10
CA2816288C (en) 2016-01-26
RU2013128430A (ru) 2014-12-27
JP6006225B2 (ja) 2016-10-12
US20130309314A1 (en) 2013-11-21
US9265835B2 (en) 2016-02-23
PL2642993T3 (pl) 2016-09-30
JP2013543874A (ja) 2013-12-09
BR112013012726B1 (pt) 2022-03-29
CN103458895A (zh) 2013-12-18
CA2816288A1 (en) 2012-05-31
EP2642993A1 (en) 2013-10-02
MY165003A (en) 2018-02-28
KR20130130727A (ko) 2013-12-02
HK1186978A1 (en) 2014-03-28
AU2011334494A1 (en) 2013-07-11
ES2572948T3 (es) 2016-06-03
JP2016028043A (ja) 2016-02-25
US20140377369A2 (en) 2014-12-25
BR112013012726A2 (https=) 2017-04-04
EP2642993B1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
KR101481643B1 (ko) 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
JP5809624B2 (ja) フルベストラントナノスフェア／ミクロスフェア並びにその調製方法及び使用
KR101539313B1 (ko) 리스페리돈의 서방성 미소구체 조성물
CN102316867B (zh) 氨氯地平微球制剂、其制备方法及应用
KR20180131077A (ko) 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR20210007924A (ko) 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법
EP3866765B1 (en) Injectable long-acting naltrexone microparticle compositions
Clark et al. Long-term delivery of ivermectin by use of poly (D, L-lactic-co-glycolic) acid microparticles in dogs
WO2008150382A1 (en) Delivery vehicles containing rosin resins
EP4454636A1 (en) Continuous delivery preparation capable of being stably released and preparation method therefor
EP3267977B1 (en) Solid dispersions
CN109419771B (zh) 十一酸睾酮缓释药物组合物、其制备方法及用途
HK1186978B (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
KR102706487B1 (ko) 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법
JP2025511372A (ja) 新規組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20181226

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20191226

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 12